Patents by Inventor Michel Rathbone

Michel Rathbone has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20110014694
    Abstract: Methods of reducing tissue damage in the nervous system are disclosed. The methods involved administering enteric glial cells to an animal with a nerve injury. Methods of improving locomotor function in animal with a nerve injury are also disclosed.
    Type: Application
    Filed: April 1, 2009
    Publication date: January 20, 2011
    Applicant: NEUROLOGICAL TECHNOLOGIES INC.
    Inventors: Shucui Jiang, Michel Rathbone
  • Publication number: 20060147425
    Abstract: Methods of promoting functional regeneration of injured nerve fibers are described. The methods involve administering enteric glial cells to an animal with a nerve injury or neurodegenerative disease. The method is also useful in inducing formation of a blood-brain barrier in the nervous system.
    Type: Application
    Filed: October 15, 2003
    Publication date: July 6, 2006
    Inventors: Michel Rathbone, Shucui Jiang, Jian Wang, Pamela Middlemiss, Mohammad Khan
  • Publication number: 20060063788
    Abstract: Disclosed herein are methods and associated compositions and medicaments directed generally to the control of cellular and neural activity and for selectively and controllably inducing the in vivo genetic expression of one or more naturally occurring genetically encoded molecules in mammals. More particularly, the present invention selectively activates or derepresses genes encoding for specific naturally occurring molecules such as proteins or neurotrophic factors and induces the endogenous production of such naturally occurring compounds through the administration of carbon monoxide dependent guanylyl cyclase modulating purine derivatives. The methods of the present invention may be used to affect a variety of cellular and neurological functions and activities and to therapeutically or prophylactically treat a wide variety of neurodegenerative, neurological, cellular, and physiological disorders.
    Type: Application
    Filed: September 29, 2005
    Publication date: March 23, 2006
    Applicant: Spectrum Pharmaceuticals, Inc.
    Inventors: Alvin Glasky, Michel Rathbone
  • Publication number: 20060025452
    Abstract: N-(Pyridinyl)-1H-indol-1-amines of formula I provide a unique combination of blocking properties for both the potassium and sodium channels. These compounds are useful for the treatment of Demyelinating Diseases and Conditions such as Multiple Sclerosis, Spinal Cord Injury, Traumatic Brain Injury and Stroke. The compounds are also useful for Stroke Rehabilitation, the treatment of Bladder Irritation and Dysfunction, and the treatment of Neuropathic Pain and Chemokine-Induced Pain.
    Type: Application
    Filed: September 27, 2005
    Publication date: February 2, 2006
    Applicant: Avenits Pharmaceuticals Inc.
    Inventors: Craig Smith, Michel Rathbone, Margaret Petty, David Rampe
  • Publication number: 20050234105
    Abstract: N-(Pyridinyl)-1H-indol-1-amines of formula I provide a unique combination of blocking properties for both the potassium and sodium channels. These compounds are useful for the treatment of Demyelinating Diseases and Conditions such as Multiple Sclerosis, Spinal Cord Injury, Traumatic Brain Injury and Stroke. The compounds are also useful for Stroke Rehabilitation, the treatment of Bladder Irritation and Dysfunction, and the treatment of Neuropathic Pain and Chemokine-Induced Pain.
    Type: Application
    Filed: March 14, 2005
    Publication date: October 20, 2005
    Applicant: Aventis Pharmaceuticals Inc.
    Inventors: Craig Smith, Michel Rathbone, Margaret Petty, David Rampe
  • Publication number: 20050159456
    Abstract: N-(Pyridinyl)-1H-indol-1-amines of formula I provide a unique combination of blocking properties for both the potassium and sodium channels. These compounds are useful for the treatment of Demyelinating Diseases and Conditions such as Multiple Sclerosis, Spinal Cord Injury, Traumatic Brain Injury and Stroke. The compounds are also useful for Stroke Rehabilitation, the treatment of Bladder Irritation and Dysfunction, and the treatment of Neuropathic Pain and Chemokine-Induced Pain.
    Type: Application
    Filed: March 14, 2005
    Publication date: July 21, 2005
    Applicant: Aventis Pharmaceuticals Inc.
    Inventors: Craig Smith, Michel Rathbone, Margaret Petty, David Rampe